2022-09-22-世界卫生组织-7._Influenza_B_Victoria_Lineage_-_Egg-derived_-_Southern_Hemisphere_2023_2页_169kb

Influenza B Victoria Lineage Vaccine Development (2023 Southern Hemisphere Season)

• Source: WHO Global Influenza Surveillance and Response System (GISRS) collaborating centres.
• Virus Type: B Victoria lineage.
• Tests: All candidate vaccine viruses (unless stated) have passed two-way haemagglutination inhibition (HI) tests.
• Vaccine Composition: Approved by national/regional control authorities.

Candidate Vaccine Viruses

1. B/Austria/1359417/2021 (Egg-derived):

   • Reassortant: BVR-26 (Classical, available from Seqirus, VIDRL, Japan's NIID, CDC).
   • Wild type: Available from NIBSC (UK), CDC.

2. B/Michigan/01/2021 (Wild type): Egg-derived.

3. B/Singapore/WUH4618/2021 (Wild type): Egg-derived.

4. B/Guangdong-Zhenjiang/1516/2021 (Wild type/Egg-derived CNIC-2107A Classical form).

5. B/Whuan/139/B/2021 (Wild type? Alternatively similar to B/Austria/1359417/2021). Wild type Egg-derived.

6. B/Victoria/2117 (B(v)-Ag-2117) from B/Austria-like.

Reference Strains & Potency Testing Reagents

• Parent and reference strains provided with potency units (µg HA/ml):
  • 2022BVA 44 (NIID, Japan)
  • 2022BVB 56 (NIID, Japan)
  • 2021/139B 90 (NIBSC, UK/TGA, Australia)
  • B(v)-Ag-2117 77 (NIBSC, UK/NIID/Japan/CDC/NYMC/VIDRL)
  • B/Austria/1359417/2021-like (Parent: BVR-26, referenced by B(v)-Ab-2119, AS446; Egg or classical)
  • B/Michigan/01/2021 (Reference: BVR-26/FDA)

Key Partners & Contact Details

• WHO Collaborating Centres (CC): CCDC (China), CDC (USA), FCI (UK), NIID (Japan), NYMC (USA), VIDRL (Australia), NIBSC (UK).
• Essential Regulatory Laboratories (ERL): CBER/FDA (USA), NIBSC (UK), NIID (Japan), TGA (Australia).
• Information: WHO CC/ERL details available online. Contact specifics for CVV/request.